A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. (Q51297641)

3 April 2018

title

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. (English)

1 reference

3 April 2018

author

Philippe L. Bedard

8

1 reference

3 April 2018

author name string

Suzanne F Jones

1

1 reference

3 April 2018

Lillian L Siu

2

1 reference

3 April 2018

Johanna C Bendell

3

1 reference

3 April 2018

James M Cleary

4

1 reference

3 April 2018

Albiruni R A Razak

5

1 reference

3 April 2018

Jeffrey R Infante

6

1 reference

3 April 2018

Shuchi S Pandya

7

1 reference

3 April 2018

Kristen J Pierce

9

1 reference

3 April 2018

Brett Houk

10

1 reference

3 April 2018

W Gregory Roberts

11

1 reference

3 April 2018

S Martin Shreeve

12

1 reference

3 April 2018

Geoffrey I Shapiro

13

1 reference

3 April 2018

publication date

4 September 2015

1 reference

3 April 2018

Investigational New Drugs

published in

1 reference

3 April 2018

volume

33

1 reference

3 April 2018

issue

5

1 reference

3 April 2018

page(s)

1100-1107

1 reference

3 April 2018

https://scigraph.springernature.com/pub.10.1007/s10637-015-0282-y

exact match

0 references

cites work

Targeting focal adhesion kinase signaling in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Control of motile and invasive cell phenotypes by focal adhesion kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Focal adhesion kinase as a regulator of cell tension in the progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

FAK integrates growth-factor and integrin signals to promote cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Multiple connections link FAK to cell motility and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

The signaling and biological implications of FAK overexpression in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Focal adhesion kinase as a cancer therapy target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

The role of focal adhesion kinase in tumor initiation and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Targeting Pyk2 for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Focal adhesion kinase: exploring Fak structure to gain insight into function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

In vitro induction of bilirubin conjugation in primary rat hepatocyte culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Functional inactivation of NF2/merlin in human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0282-Y

Focal adhesion kinase as potential target for cancer therapy (Review).

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26334219

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26334219

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-015-0282-Y

1 reference

3 April 2018

PubMed ID

26334219

1 reference

3 April 2018